| JURCZYSZYN, A, A WASZCZUK-GAJDA, JJ CASTILLO, K KRAWCZYK, Martin ŠTORK, L POUR, L USNARSKA-ZUBKIEWICZ, S POTOCZEK, I HUS, JD VALLS, P HARI, S CHHABRA, M GENTILE, G MIKALA, G VARGA, CS CHIM, M FIALA, R VIJ, N SCHUTZ, M RODZAJ, A POROWSKA, DH VESOLE, A DRUZD-SITEK, J WALEWSKI and AK NOOKA. Primary refractory multiple myeloma: a real-world experience with 85 cases. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2020, vol. 61, No 12, p. 2868-2875. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2020.1788014. |
Other formats:
BibTeX
LaTeX
RIS
@article{1740559,
author = {Jurczyszyn, A and WaszczukandGajda, A and Castillo, JJ and Krawczyk, K and Štork, Martin and Pour, L and UsnarskaandZubkiewicz, L and Potoczek, S and Hus, I and Valls, JD and Hari, P and Chhabra, S and Gentile, M and Mikala, G and Varga, G and Chim, CS and Fiala, M and Vij, R and Schutz, N and Rodzaj, M and Porowska, A and Vesole, DH and DruzdandSitek, A and Walewski, J and Nooka, AK},
article_location = {LONDON},
article_number = {12},
doi = {http://dx.doi.org/10.1080/10428194.2020.1788014},
keywords = {Double-refractory multiple myeloma; prognosis; treatment response; survival},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
note = {Bez afiliace k MU.},
title = {Primary refractory multiple myeloma: a real-world experience with 85 cases},
volume = {61},
year = {2020}
}
TY - JOUR
ID - 1740559
AU - Jurczyszyn, A - Waszczuk-Gajda, A - Castillo, JJ - Krawczyk, K - Štork, Martin - Pour, L - Usnarska-Zubkiewicz, L - Potoczek, S - Hus, I - Valls, JD - Hari, P - Chhabra, S - Gentile, M - Mikala, G - Varga, G - Chim, CS - Fiala, M - Vij, R - Schutz, N - Rodzaj, M - Porowska, A - Vesole, DH - Druzd-Sitek, A - Walewski, J - Nooka, AK
PY - 2020
TI - Primary refractory multiple myeloma: a real-world experience with 85 cases
JF - LEUKEMIA & LYMPHOMA
VL - 61
IS - 12
SP - 2868-2875
EP - 2868-2875
PB - INFORMA HEALTHCARE
SN - 10428194
N1 - Bez afiliace k MU.
KW - Double-refractory multiple myeloma
KW - prognosis
KW - treatment response
KW - survival
N2 - This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
ER -
JURCZYSZYN, A, A WASZCZUK-GAJDA, JJ CASTILLO, K KRAWCZYK, Martin ŠTORK, L POUR, L USNARSKA-ZUBKIEWICZ, S POTOCZEK, I HUS, JD VALLS, P HARI, S CHHABRA, M GENTILE, G MIKALA, G VARGA, CS CHIM, M FIALA, R VIJ, N SCHUTZ, M RODZAJ, A POROWSKA, DH VESOLE, A DRUZD-SITEK, J WALEWSKI and AK NOOKA. Primary refractory multiple myeloma: a real-world experience with 85 cases. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2020, vol.~61, No~12, p.~2868-2875. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2020.1788014.
|
